Silk Road Medical
Market Cap
US$1.7b
Last Updated
2021/04/11 22:30 UTC
Data Sources
Company Financials +
Executive Summary
Silk Road Medical, Inc. operates as a medical device company in the United States. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Adequate balance sheet with limited growth.
Similar Companies
Share Price & News
How has Silk Road Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SILK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: SILK's weekly volatility (7%) has been stable over the past year.
Market Performance
7 Day Return
-1.9%
SILK
2.9%
US Medical Equipment
2.1%
US Market
1 Year Return
38.9%
SILK
40.4%
US Medical Equipment
56.3%
US Market
Return vs Industry: SILK underperformed the US Medical Equipment industry which returned 40.4% over the past year.
Return vs Market: SILK underperformed the US Market which returned 56.3% over the past year.
Shareholder returns
| SILK | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.9% | 2.9% | 2.1% |
| 30 Day | -5.1% | 3.9% | 2.4% |
| 90 Day | -15.9% | 1.0% | 6.1% |
| 1 Year | 38.9%38.9% | 41.6%40.4% | 59.1%56.3% |
| 3 Year | n/a | 78.6%74.4% | 65.7%55.1% |
| 5 Year | n/a | 143.1%126.1% | 122.3%97.6% |
Long-Term Price Volatility Vs. Market
How volatile is Silk Road Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Update: Silk Road Medical (NASDAQ:SILK) Stock Gained 37% In The Last Year2 months ago | Simply Wall St
Calculating The Intrinsic Value Of Silk Road Medical, Inc (NASDAQ:SILK)3 months ago | Simply Wall St
Silk Road Medical, Inc's (NASDAQ:SILK) Profit OutlookValuation
Is Silk Road Medical undervalued compared to its fair value and its price relative to the market?
15.97x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SILK's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SILK's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SILK is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: SILK is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SILK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SILK is overvalued based on its PB Ratio (16x) compared to the US Medical Equipment industry average (5x).
Future Growth
How is Silk Road Medical forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
5.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SILK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SILK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SILK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SILK's revenue (24.7% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: SILK's revenue (24.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SILK is forecast to be unprofitable in 3 years.
Past Performance
How has Silk Road Medical performed over the past 5 years?
9.4%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: SILK is currently unprofitable.
Growing Profit Margin: SILK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if SILK's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare SILK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SILK is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).
Return on Equity
High ROE: SILK has a negative Return on Equity (-44.06%), as it is currently unprofitable.
Financial Health
How is Silk Road Medical's financial position?
Financial Position Analysis
Short Term Liabilities: SILK's short term assets ($173.3M) exceed its short term liabilities ($19.6M).
Long Term Liabilities: SILK's short term assets ($173.3M) exceed its long term liabilities ($52.3M).
Debt to Equity History and Analysis
Debt Level: SILK's debt to equity ratio (45.1%) is considered high.
Reducing Debt: Insufficient data to determine if SILK's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SILK has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SILK has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 16.5% each year
Dividend
What is Silk Road Medical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SILK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SILK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SILK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SILK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SILK's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.1yrs
Average management tenure
CEO
Erica Rogers (56 yo)
8.5yrs
Tenure
US$3,679,061
Compensation
Ms. Erica J. Rogers serves as the Chief Executive Officer and President of Silk Road Medical Inc since October 2012. Ms. Rogers serves as Director at Sight Sciences, Incorporated since December 2019. She i...
CEO Compensation Analysis
Compensation vs Market: Erica's total compensation ($USD3.68M) is about average for companies of similar size in the US market ($USD3.67M).
Compensation vs Earnings: Erica's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: SILK's management team is considered experienced (3.1 years average tenure).
Board Members
Experienced Board: SILK's board of directors are considered experienced (8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.6%.
Top Shareholders
Company Information
Silk Road Medical, Inc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Silk Road Medical, Inc
- Ticker: SILK
- Exchange: NasdaqGS
- Founded: 2007
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$1.723b
- Shares outstanding: 34.37m
- Website: https://silkroadmed.com
Number of Employees
Location
- Silk Road Medical, Inc
- 1213 Innsbruck Drive
- Sunnyvale
- California
- 94089
- United States
Listings
Biography
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularizati...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/11 22:30 |
| End of Day Share Price | 2021/04/09 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.